SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Federal reclassification of cannabis and the elimination of the 280E tax barrier are driving significant attention to Weedcoin, as the community positions it as a key beneficiary of these policy changes on Solana. Enthusiasts are rallying around its 

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community actively champions the "OG meme" narrative of Rage Comics, viewing it as the foundational "meme reset." This dedicated base is passionately building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and widespread recognition as they aim to lead the next major meme coin cycle.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume driven by news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. This announcement has ignited a fierce debate within the trading community, with many anticipating a short squeeze due to the stock's low float, while others express caution regarding potential dilution and pump-and-dump dynamics.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending amid recent regulatory approvals for a key acquisition and an analyst firm initiating coverage with an "Overweight" rating. While some investors voice frustration over past delays in commercial revenue and management communication, a significant portion of the community maintains strong conviction in the long-term potential of its specialized isotope technology for critical sectors including advanced energy, medical applications, and next-generation computing. The conversation highlights a divide between those concerned about execution timelines and those focused on strategic asset accumulation and the company's unique market position.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF is generating significant buzz as investors grapple with its perceived disconnection from the underlying asset. Intense community discussions center on the impact of distributions and the inherent decay of this leveraged product, leading to a polarized debate over its immediate trajectory and risk profile.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is seeing significant community discussion driven by the departure of its CFO, which has sparked diverse speculation about a potential acquisition, alongside a new expanded access agreement for its rare disease treatment, MIPLYFFA, to broaden global reach. Simultaneously, investors are closely watching the ongoing legal proceedings with Commave, with varying interpretations of recent court developments influencing sentiment around the future of its KP1077 asset.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending significantly following the FDA's Complete Response Letter to competitor Corcept Therapeutics for its Cushing's syndrome treatment. This outcome is widely viewed by the community and analysts as a "massive tailwind" for Xeris's Recorlev, strengthening its market position in a growing multi-billion dollar sector. Investors are actively discussing this enhanced competitive moat and the promising future of its XP-8121 pipeline.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending amid intense community debate surrounding mixed interim Phase 2 data for its cystic fibrosis therapy, ARCT-032, where positive mucus plug reduction signals are being weighed against limited lung function improvement. Concurrently, investors are closely following a high-stakes trade secret lawsuit against AbbVie, which many believe could lead to a significant settlement or buyout, fueling conversations about the stock's perceived undervaluation and potential for a substantial short squeeze.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending after definitively agreeing to sell Bressner Technology for $22.4M, a strategic move the community views as a profitable pivot to focus on high-growth AI and edge computing. This substantial cash infusion and sharpened corporate focus are fueling strong anticipation for impending large military contracts, particularly a potential $200M situational awareness system. Investors are actively discussing the company's low float and undervalued status, anticipating significant upside as the AI and defense narrative gains wider recognition.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after receiving an FDA Complete Response Letter for its relacorilant drug aimed at Cushing's syndrome, leading to a significant stock decline. Community discussions are heavily focused on whether this market reaction is an extreme overreaction, given the company's established revenue-generating drug and additional pipeline assets. Many investors are now evaluating the stock as a potential rebound play, anticipating management's forthcoming discussions with the FDA to address the decision.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Essent Group Ltd. $ESNT Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al trimmed its holdings in Essent Group Ltd. (NYSE:ESNT - Free Report) by 8.6% in the third quarter, according to its most recent disclosure with the Securities...

Pacer Advisors Inc. Purchases 21,171 Shares of Essent Group Ltd. $ESNT

Pacer Advisors Inc. grew its position in Essent Group Ltd. (NYSE:ESNT - Free Report) by 531.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and...

Voya Investment Management LLC Sells 74,863 Shares of Essent Group Ltd. $ESNT

Voya Investment Management LLC cut its holdings in shares of Essent Group Ltd. (NYSE:ESNT - Free Report) by 32.7% in the 3rd quarter, according to its most recent disclosure with the Securities and...

Essent Group (NYSE:ESNT) SVP Sells 4,352 Shares

Essent Group Ltd. (NYSE:ESNT - Get Free Report) SVP Mary Lourdes Gibbons sold 4,352 shares of Essent Group stock in a transaction on Thursday, December 18th. The shares were sold at an average price...

Insider Selling: Essent Group (NYSE:ESNT) SVP Sells 4,352 Shares of Stock

Essent Group Ltd. (NYSE:ESNT - Get Free Report) SVP Mary Lourdes Gibbons sold 4,352 shares of the business's stock in a transaction on Thursday, December 18th. The shares were sold at an average...

Thrivent Financial for Lutherans Sells 66,289 Shares of Essent Group Ltd. $ESNT

Thrivent Financial for Lutherans cut its holdings in shares of Essent Group Ltd. (NYSE:ESNT - Free Report) by 41.2% during the 2nd quarter, according to its most recent Form 13F filing with the...

Essent Group (NYSE:ESNT) Sets New 12-Month High - Time to Buy?

Essent Group (NYSE:ESNT) Hits New 12-Month High - What's Next...

Invesco Ltd. Reduces Stock Position in Essent Group Ltd. $ESNT

Invesco Ltd. decreased its holdings in Essent Group Ltd. (NYSE:ESNT - Free Report) by 13.9% during the second quarter, according to the company in its most recent disclosure with the Securities...

Essent Group Ltd. $ESNT Stock Position Decreased by First Trust Advisors LP

First Trust Advisors LP decreased its holdings in shares of Essent Group Ltd. (NYSE:ESNT - Free Report) by 22.4% during the 2nd quarter, according to the company in its most recent disclosure with...

Essent Group Ltd. $ESNT Stake Decreased by Hsbc Holdings PLC

Hsbc Holdings PLC trimmed its holdings in Essent Group Ltd. (NYSE:ESNT - Free Report) by 53.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange...

Essent Group Ltd. is a holding company, which engages in the provision of banking services. It offers mortgage insurance, reinsurance, and risk management products. The company was founded by Mark A. Casale on July 1, 2008 and is headquartered in Hamilton, Bermuda.

Current Price	$65.01
Prev Close	$65.68
Open	$65.71
Dividend Yield	2.06%
50-Day Moving Average	$62.63
Beta	0.70
Avg. Volume	597,624.00
PE Ratio	9.46

52-Week High	$67.09
52-Week Low	$51.61
Market Capitalization	$6.35B
EPS (Annual)	$6.85
Price to Book	1.10
Revenue Per Employee	$1.95M
Enterprise Value/EBITDA	N/A

ESNT
Essent Group Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ESNT News

ESNTEssent Group Ltd